Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti

Abstract We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppress...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Open Forum Infectious Diseases 2021-12, Vol.8 (12), p.ofab559-ofab559
Hauptverfasser:	Pierre, Samuel, Bocharova, Iryna, Nguyen, Catherine, Homeus, Fabienne, Julmiste, Gaetane, Macius, Youry, Rouzier, Vanessa, Severe, Patrice, Marcelle Deschamps, Marie, Moise, Colette Guiteau, Bellot, Clovy, Wu, Johnny, Rivera, Vanessa R, Sun, Rochelle, Pape, Jean W, Liautaud, Bernard, Koenig, Serena P
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-HIV agents Antiviral agents Brief Reports Care and treatment Darunavir DNA polymerases Highly active antiretroviral therapy HIV (Viruses) Proteases Reverse transcriptase inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.
ISSN:	2328-8957 2328-8957
DOI:	10.1093/ofid/ofab559